Patrys Ltd (ASX:PAB)’s James Campbell speaks with Proactive’s Elisha Newell about the company’s successful engineering run to produce large-scale quantities of clinical grade PAT-DX1. It Is believed that PAT-DX1 may have application across a wide range of cancers including gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers. Campbell explains the company is now a step closer to clinical trial of the tumour-targeting PAT-DX1 after this second engineering run produced large-scale quantities of the antibody. The PAB CEO says that if the batch meets specifications, the manufactured PAT-DX1 antibody should supply sufficient PAT-DX1 for the company to conduct final pre-clinical toxicology studies in preparation for a proposed Phase 1 clinical trial in the second half of 2023.
Patrys remains on track to produce large-scale quantities of clinical grade PAT-DX1
